Mizuho raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $20 from $19 and keeps an Outperform rating on the shares. The firm says Arcutis is a top pick for 2025 and that it expects the company to start 2025 positively. It increased Q4 and 2025 Zoryve franchise sales estimates above consensus based on better than expected Q4 script trends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls
- Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright
- Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings
- Arcutis Biotherapeutics submits sNDA for ZORYVE cream to FDA
- Arcutis Biotherapeutics announces promotions on executive management team